Extended Data Fig. 6. In vivo activity of engineered mAb variants.

a–d, Mosquito-bite parasitaemia survival curves for 13 variants (n = 10 mice), including the eight that had the best aggregate score from the developability assays. e, Sporozoite liver burden percent inhibition compared to untreated, infected mice (geometric mean, n = 5) and normalized to the activity of AB-000317, lines and bars indicate mean ± SEM, 2–5 independent experiments per mAb, **P = 0.005 or P > 0.05 for all other variants, two-tailed Dunn’s multiple comparisons test verses AB-000317 (see Extended Data Table 3 for details).